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Background and aims: The non-steroidal anti-inflammatory drug sulindac is an effective 
chemopreventive agent in sporadic colorectal cancer but its potential benefit in mismatch 
repair deficient cancers remains to be defined. We wanted to determine whether genetic 
defects that are relevant for colorectal cancer, such as Msh2 or p53 deficiency, would 
influence the efficiency of sulindac chemoprevention or increase the side effects. 
Methods: Msh2 or p53 deficient and wild type mice received feed containing 160-320 ppm 
sulindac for up to 25 weeks with or without a concurrent treatment with the carcinogen 
azoxymethane. Colon tissue was analysed by histopathology and molecular biology methods. 
Results: We show that sulindac prevented azoxymethane-induced distal colon tumours in all 
mice. In the proximal colon, however, sulindac induced new inflammatory lesions on the 
mucosal folds, which further developed into adenocarcinoma in up to 18-25% of the p53 or 
Msh2 deficient mice but rarely in wild type mice. This region in the proximal colon was 
characterised by a distinct profile of pro- and anti-inflammatory factors, which were 
modulated by the sulindac diet, including upregulation of Hypoxia Inducible Factor 1α and 
Macrophage Inflammatory Protein 2. 
Conclusions: These data show that the sulindac diet promotes carcinogenesis in the mouse 
proximal colon possibly through chronic inflammation. Sulindac has both beneficial and 
harmful effects in vivo, which are associated with different microenvironments within the 
colon of experimental mice. Deficiency for the Msh2 or p53 tumour suppressor genes 
increases the harmful side effects of long-term sulindac treatment in the mouse colon. 
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SUMMARY 
What is already known about this subject 
• NSAID sulindac prevents tumours in many animal models of colorectal cancer and 
has also shown some promise in clinical trials. 
• Long-term use of some NSAIDs is associated with significant gastrointestinal side 
effects. 
• There are conflicting reports on the efficacy of sulindac in ApcMin mice, raising 
questions as to whether certain germline or somatic gene defects reduce the efficiency 
of chemoprevention or increase the side effects. 
What are the new findings 
• We show that sulindac prevented carcinogenesis in the distal colon of wild type and 
p53 or mismatch repair deficient mice. 
• However sulindac induced new inflammatory lesions in the mouse proximal colon, 
which progressed to malignancy more frequently in p53 or mismatch repair deficient 
mice. 
• The premalignant changes started from mild surface damage in the colon epithelium, 
which progressed to chronic inflammation if the sulindac diet was maintained. 
• This region in the proximal colon was characterised by a distinct profile of pro- and 
anti-inflammatory factors, which were differentially modulated by the sulindac diet, 
including upregulation of MIP-2 and Hif1α.  
• Sulindac has both beneficial and harmful effects in vivo, which are associated with 
different microenvironments within the colon. 
How might it impact on clinical practice in the foreseeable future 
• It is unlikely that sulindac use in humans leads to as serious side effects as in the 
genetically modified Msh2 or p53 deficient mice. 
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INTRODUCTION 
The great potential of non-steroidal anti-inflammatory drugs (NSAIDs) in cancer 
chemoprevention has been recognised for decades.[1]  For example, in a recent clinical trial 
of aspirin in the Lynch syndrome, there was a long term reduction in the incidence of 
colorectal carcinoma after the trial had been concluded.[2,3] Lynch syndrome patients are 
carriers of DNA mismatch repair (MMR) gene mutations and have a high risk of developing 
recurrent tumours. The data on sulindac in the Lynch syndrome are limited, but short-term 
administration of sulindac increased epithelial cell proliferation in the proximal colon of 
MMR mutation carriers, raising concerns about its potential chemopreventive effect.[4] The 
NSAIDs celecoxib and rofecoxib reduced the risk of sporadic colorectal adenomas in clinical 
trials, but were associated with serious side effects, including cardiovascular problems or 
gastrointestinal ulcers, bleeding and obstructions.[5,6] Subsequently, rofecoxib was 
withdrawn from clinical use in arthritis but other NSAIDs are among the most commonly 
used medicines.  
It is now widely recognised that apart from gastroduodenal toxicity, NSAIDs also 
have significant side effects in the colon, such as non-specific, eosinophilic or ischemic 
colitis, ulcers, strictures and exacerbation of colonic diverticular disease.[7] This implies that 
NSAIDs can have diametrically opposed effects on the colon, chemoprevention of tumours 
on the one hand and induction or exacerbation of inflammation on the other. Chronic 
inflammation can lead to carcinogenesis, as is well known in chronic colitis and the dextran 
sodium sulfate mouse model of this disease.[8,9] 
The mechanism of NSAID chemoprevention and the cause of the side effects in vivo 
remain unclear. NSAIDs are highly effective in preventing tumour development in some 
animal models, such as the azoxymethane (AOM) model of colorectal cancer in rats and in 
p53∆/+ or p53∆/∆ mice.[10,11] Dietary sulindac also caused a significant decrease in the 
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number of polyps in ApcMin mice.[12] However, a subsequent study reported a decrease of 
tumour development in the small intestine of ApcMin mice but an increase of incidence, 
multiplicity and volume of tumours in the colon, especially in the caecum, with a sulindac 
diet.[13] In the Apc∆/+Msh2∆/∆ mice no difference was observed in the numbers of polyps or 
aberrant crypt foci (ACF) in the colon between mice receiving control diet, sulindac or a 
specific COX-2 inhibitor, MF-tricyclic.[14] 
Therefore, we wanted to determine whether genetic defects that are found in 
hereditary or sporadic colorectal cancer, such as the MMR or p53 deficiency, would 
influence the efficiency of sulindac chemoprevention in vivo, or increase the side effects of 
this treatment. We chose to use sulindac as it has been commonly used in mice and rats, and 
to compare its effect in wild type, Msh2∆/∆ and p53∆/∆ mice. Deficiency of the MSH2 gene 
causes a MMR defect, which is found in Lynch syndrome cancers and a subset of sporadic 
cancers, and p53 is a common defect in sporadic cancers. As neither the p53∆/∆ mice nor the 
Msh2∆/∆ mice develop spontaneous colorectal tumours, we used the carcinogen AOM to 
induce tumours in the distal colon. Although many features of AOM-induced tumours in wild 
type mice or rats are consistent with sporadic colorectal cancer in humans,[15] a striking 
discrepancy is the absence of both the p53 and Msh2 gene defects. Here, we have addressed 
this issue by using genetically modified strains, which allow separate assessment of each 
defect in the AOM model.  
 
MATERIALS AND METHODS 
Mouse lines 
HIF1αF/F were crossed with VILcre mice (B6.SJL-Tg(vil-cre)997Gum/J; Jackson 
Laboratories, Bar Harbor, Maine)[16,17] and heterozygous HIF1α∆/+ knockout mice to 
produce the test genotype VILcrecre/+HIF1α∆/F, which are deficient for HIF1α in the 
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intestinal epithelial cells (∆IEC), and the control genotype VILcre+/+HIF1α∆/F, which 
expresses HIF1α from the floxed (F) allele. Recombination efficiency in the colon was 
determined as previously described.[18] Msh2∆/∆, p53∆/∆, p53∆/+, and the corresponding wild 
type (WT) siblings were obtained by crossing heterozygotes.[19,20] All mice were on the 
C57Bl/6J background. 
 
Administration of AOM and sulindac 
Mice (8 weeks old) were given three weekly injections (15 mg/kg) of AOM (Sigma-
Aldrich, St Louis, MO) or vehicle (saline) only and feed containing either 160 (half) or 320 
ppm (full) sulindac (Sigma-Aldrich; Specialty Feeds, Glen Forrest, Western Australia) for 22 
weeks (started 2 weeks prior to AOM) or control feed.[10,11] Additional groups of mice 
received the sulindac diet without AOM treatment for 1-25 weeks. Colons were opened 
longitudinally and all distal tumours and proximal lesions, which were visible under a 
dissecting microscope, were counted and measured. The total surface area of tumours or 
lesions per mouse was determined as previously described.[21] A subset of colons were 




All visible lesions and tumours from each colon were biopsied for histopathology 
analysis together with biopsies of macroscopically normal tissue. The entire length of the 
biopsies was examined equivalent to 7-14 high power fields. The severity of inflammation 
was assessed over the entire area that was inflamed. All specimens, including untreated 
controls, were analysed by an anatomical pathologist (JED). Assessment was conducted 
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using blinded slides, and findings were peer-reviewed by a second pathologist for 
concordance.   
The features assessed included: acute and/or chronic inflammation, lymphoid 
aggregates, hyperplastic and /or degenerative changes of the surface epithelium, architectural 
distortion, fibrosis, and neoplasia, classified as epithelial dysplasia or adenocarcinoma. 
Dysplasia was graded as negative, indefinite for low-grade dysplasia, low-grade and high-
grade dysplasia according to the Riddell classification.[22] Only biopsies that show 
convincing neoplastic glands within a desmoplastic stroma extending beyond the muscularis 
mucosae were regarded as invasive adenocarcinoma. Some proximal colon biopsies with 
severe inflammation showed bland appearing displaced glands extending through the 
muscularis mucosae, which on occasion even showed some mucin distension associated with 
these glands. These were regarded as pseudoinvasion or lesions of colitis cystica profunda.  
Ulceration was defined as loss of the colonic mucosa associated with an acute 
inflammatory reaction extending at least through the muscularis mucosae. An erosion was 
defined as superficial ulceration that involved only the surface epithelium and superficial 
underlying lamina propria. Mild acute inflammation was arbitrarily defined as the presence of 
5-30 neutrophils per high power field in the mucosa. Mild chronic inflammation was 
arbitrarily defined as 30-200 chronic inflammatory cells in the superficial and deep lamina 
propria /high power field without significant distortion of the crypt architecture. Severe 
chronic inflammation involved >500 chronic inflammatory cells/high power field causing 
expansion of the lamina propria and extending at least into the submucosa. Hyperplastic 
change was defined as an increase in the number of epithelial cells in the lining mucosa often 
associated with a “frilly” appearance of the surface epithelium similar to hyperplastic polyps 
in the human colon. Number of apoptotic cells/crypt column was assessed from H&E stained 
colon sections as previously described,[13] based on morphological features, including cell 
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shrinkage, nuclear condensation and presence of apoptotic bodies. Minimum of 20 crypts (40 
crypt columns) were counted. 
 
mRNA and protein analysis 
The mucosal surface of the proximal lesions and the uninvolved tissue from 
proximal and distal colon was lightly scraped and snap frozen in liquid nitrogen for RNA 
extraction. Q-PCR reactions were performed using SYBRgreen, TaqMan assays (Applied 
Biosystems, Foster City, CA) or UPL assays (Roche Applied Science) on ABI Prism 7900-
HT Real Time PCR system (Applied Biosystems). For protein analysis snap frozen mouse 
tissues were homogenised in standard RIPA buffer and the resulting lysates analysed with 
western blotting (primary antibodies for cleaved caspase 3, 1:1000, #9661, BclxL, 1:1000, 
#2764, Bcl-2, 1:1000, #2870s, Cell Signaling Technology, Beverly, MA, Bax, 1:1000, sc-
493, p21, 1:500, sc-397-G, Santa Cruz Biotechnology, Santa Cruz, CA, and ß-actin, 1:10000, 
clone AC15, Sigma-Aldrich). 
 
Cell line analysis 
HCT15 cells (CCL-225™, ATCC, Manassas, VA, USA) were propagated in RPMI 
1640 media supplemented with FBS (10% (v/v), Thermotrace, Noble Park, VIC, Australia). 
Cells were incubated overnight in reduced serum conditions (0.2% FBS) and were stimulated 
with TNFα (Peprotech Inc., Rocky Hill, NJ) or sulindac sulfide (Sigma-Aldrich), dissolved in 
the vehicle control DMSO (Sigma-Aldrich). 
 
Immunohistochemistry 
Colon tissue was fixed in 10% formalin and embedded in paraffin following 
standard procedures. Sections were incubated with the following antibodies: HIF1α (1:100, 
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60 min, sc-8711, Santa Cruz Biotechnology, Santa Cruz, CA); Ki67 (1:200, 60 min, clone 
SP6, NeoMarkers, Fremont, CA). Positive and negative control for Hif1α was generated by 
incubating freshly isolated pieces of colon tissue in special media as previous described in 
hypoxic (1% oxygen) or normoxic conditions for 4 h.[23] Hif1α expression intensity (H 
score) was calculated by summing the products of the percentage of positively stained surface 
epithelial cells (0–100) and the staining intensity (1, 2 or 3). 
For analysis of hypoxia, mice were injected with 60 mg/kg pimonidazole HCl 
(Natural Pharmacia International, Burlington, MA), a well validated hypoxia marker,[24] and 
sacrificed after 3 h. Hypoxic areas of the colon were detected by incubating tissue sections 
with monoclonal antibody raised against pimonidazole (1:10, 40 min, Natural Pharmacia 
International). Antibody binding was visualized with the Animal Research Kit (ARK™, 
DAKO). Positive and negative controls were generated by incubating colon tissue with 
50µg/ml pimonidazole HCl for 2 h in hypoxic or normoxic conditions. 
 
Measurement of drug concentration in colon mucosa 
Colon mucosa was lightly scraped and snap frozen, then weighed and homogenised in liquid 
nitrogen. Sulindac and its metabolites, sulindac sulfone and sulindac sulfide, were extracted 
as previously described[25] and analysed with a Thermo Scientific Quantum Access triple 
quadrupole mass spectrometer coupled to a Thermo Scientific Accela UHPLC system 
(Thermo Fisher Scientific, Waltham, MA). Quantitation was performed using external 




Gene/protein expression and sulindac metabolites in tissue were compared using t-tests, and 
the overall frequencies of neoplasia with Fisher’s Exact Test. Severity of inflammation, 
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numbers of apoptotic cells/crypt column, number/size of tumours or lesions and Bax/BclxL, 
Bax/Bcl2 ratios were compared using the Wilcoxon Mann Whitney test (StatXact 8, Cytel 
Software Corporation, Cambridge, MA). 
 
RESULTS 
Sulindac prevents carcinogenesis in the distal colon regardless of mouse genotype. 
Carcinogenesis was induced in the distal colon by administration of the carcinogen 
AOM (fig 1A-C), and both the Msh2∆/∆ and p53∆/∆ mice developed significantly more and 
larger tumours than their wild type (WT) littermates (p=0.035 and p=0.015, respectively). All 
mice receiving a diet containing sulindac developed fewer and smaller tumours and this 
effect was dose-dependent (fig 1B,C). Histopathology analysis showed that the sulindac 
treatment also reduced the frequency of neoplasia (fig 1D, supplementary table 1).  
 
Sulindac triggers carcinogenesis in the proximal colon. 
Examination of methylene blue stained colons revealed new lesions developing as a 
result of the sulindac diet in the mucosal folds of the proximal colon (fig 1E), in contrast with 
the AOM-induced tumours, which were located within 2 cm from the anus. Very few 
proximal lesions were detected when mice received AOM treatment alone, i.e. without 
sulindac diet, and both doses of sulindac treatment led to a highly significant increase in both 
the number and size of lesions in all genotypes including the WT (fig 1F,G). The 
macroscopic appearance ranged from obvious thickening of the mucosal folds to clearly 
defined flat lesions on the mucosal folds. Histopathology analysis revealed that the lesions 
ranged from acute and chronic inflammation through to dysplasia and invasive carcinoma 
(fig 1D, fig 2A-E). Adenocarcinoma was found in up to 25% of Msh2 and 18% of the p53 
deficient mice, but at the most in only one WT mouse in the sulindac-treated groups 
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(supplementary table 1). Subsets of Msh2 or p53 deficient mice that did not receive the 
carcinogen AOM treatment also developed neoplasia in the proximal colon either with the 
full sulindac or the half sulindac diet (fig 1H, supplementary table 1). There was no statistical 
difference in the frequency of proximal adenocarcinoma between the groups that received 
AOM+sulindac or sulindac alone. This indicates that the effect of sulindac was not due to an 
interaction with AOM. There was very good agreement between the two pathologists for 
diagnosing adenocarcinoma (kappa = 0.969). 
We then carried out a systematic pathology comparison between the lesions and 
tumours in the proximal and distal colon and the surrounding uninvolved mucosa 
(supplementary tables 2-3). Hyperplastic changes were more common in the proximal lesions 
(up to 100%) than in the distal tumours (up to 25%). Mucinous adenocarcinomas and tissue 
ulceration were only found in the proximal colon. Tissue damage (erosion and ulceration) 
was more frequent in the lesions than surrounding uninvolved tissue in all genotype groups 
(p<0.0001) but was also found in the surrounding mucosa.  
 
Sulindac metabolites accumulate in the colon mucosa. 
Much of the water absorption from the bolus occurs at the mucosal folds in the 
proximal colon where the faecal material is still in semi-liquid form, while the faeces are 
solid in the distal colon. To test whether sulindac contained in the semi-liquid bolus causes a 
higher accumulation of drug in the proximal colon, we measured the concentrations of 
sulindac and its two metabolites, sulfide and sulfone in the mucosal lining. Sulindac 
concentration was low (fig 2F), whereas its derivatives accumulated at higher concentrations 
than the pro-drug. Sulfone and sulfide concentrations were marginally higher in the proximal 




Premalignant proximal lesions develop in a defined region of the proximal colon.  
We treated additional groups of WT littermates from the p53 line with the full 
sulindac diet to analyse the development of the proximal premalignant lesions. Small lesions 
were visible under the dissecting microscope after 1 week but the lesions were significantly 
larger from 10-20 weeks, and the number of lesions per mouse increased at 20 and 25 weeks 
(supplementary fig 1). Histopathology analysis revealed infiltration of inflammatory cells as 
early as one week after sulindac treatment. Depth of inflammation in the lesions progressed 
from mucosal (1 week sulindac treatment) to transmural (25 weeks), as well as crypt damage 
from surface crypt and epithelium damage (1 week) to entire crypt and epithelium lost (25 
weeks, supplementary fig 1). Most lesions were found in a defined 1 cm region of the 
mucosal folds (fig 2G). This region was labelled as P2 in subsequent analyses. 
 
Sulindac-induced inflammation is associated with a slight increase of epithelial cell 
apoptosis  
Sulindac-associated carcinogenesis is associated with a decrease of apoptosis in the 
caecum of ApcMin mice.[13] We next determined if we could observe changes in the rate of 
apoptosis after sulindac treatment. There was a 8.3-fold increase in the number of apoptotic 
cells/crypt column in the lesions (p=0.05) and a 4-fold increase (p=0.08) in the surrounding 
tissue compared to WT mice receiving control food. This increase was not seen in the middle 
and distal colon in sulindac treated mice (supplementary table 4). Western blot analysis for 
the apoptotic marker cleaved caspase 3 also demonstrated a slight increase of apoptosis in the 
P2 region of sulindac treated mice (fig 3A). We next assessed pro- and anti-apoptotic markers 
Bax, Bcl-xL and Bcl-2 by western blot and qPCR analysis and determined the ratio of 
Bax/Bcl-xL and Bax/Bcl2, which can indicate changes in the sensitivity of cells to apoptosis. 
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These ratios remained similar in the mice treated with sulindac compared to control mice, 
with minor increases in the proximal colon (supplementary fig 2). Thus we did not observe a 
decrease but a slight increase of apoptosis, which may be explained by increased 
inflammation as previously reported in ulcerative and experimental colitis.[26,27] We also 
examined p21, which mediates the chemopreventive effect of sulindac in Apc1638+/- 
mice.[28] p21 expression was not significantly changed in the P2 region, but there was a 
small but significant increase in the distal colon (fig 3B).  
 
Sulindac modulates expression of pro-inflammatory genes in the colon. 
As colon neoplasia was clearly associated with the inflammatory lesions in sulindac 
fed mice, we next examined a panel of pro- and anti-inflammatory factors, which have been 
previously implicated in mouse models of colon inflammation, such as HIF1α and NFκB 
target genes. Constitutive expression of HIF1α augments inflammation in experimental 
colitis[29] and the NFκB pathway links inflammation and cancer in the AOM/DSS model of 
colitis.[9] We detected strong upregulation of HIF1α by sulindac in the lesions and in the 
uninvolved mucosa at the P2 region (fig 4A). Of the NFκB target genes,[9,29] the most 
striking effect was seen for MIP-2, IL1β and COX-2, which were very strongly upregulated 
by the sulindac diet in the lesions (fig 4A). A20 an anti-inflammatory and anti-apoptotic 
factor,[30] was slightly downregulated in the P2 region, but the expression of other NFkB 
target genes IL6, TNFα and ICAM was variable and they were not strongly upregulated by 
the sulindac diet (fig 4A). We also examined PECAM, which mediates transendothelial 
leukocyte migration in experimental colitis,[31] and found that it was slightly upregulated in 
the lesions. iNOS was upregulated by the sulindac diet only in the distal colon. 
As we observed strong MIP-2 upregulation in the mucosal lining throughout the 
colon in sulindac-treated mice, we next tested whether sulindac has the same effect in vitro 
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independent of inflammatory cells. MIP-2 is the mouse homolog of IL8, a chemokine that is 
overexpressed in many solid cancers and causes recruitment of infiltrating neutrophils to the 
tumour microenvironment.[32] We treated the COX-2 deficient human colon cancer cell line 
HCT15 with sulindac sulfide. This treatment resulted in nearly 40-fold upregulation of IL8 
but only 2-3 fold upregulation of TNFα and ICAM and had no effect on IL6 expression (fig 
4B). TNFα treatment of HCT15 cells was used as a positive control to demonstrate strong 
upregulation of IL8, ICAM and TNFα upon cytokine stimulation.[33] Therefore, we conclude 
that the sulindac diet can differentially modulate the expression of pro-inflammatory genes in 
the proximal and distal colon mucosa and that the sulindac-induced lesions have the highest 
expression of pro-inflammatory factors. 
 
Sulindac diet induces HIF1α  overexpression in the site susceptible to lesions. 
HIF1α is a transcription factor that regulates many aspects of cancer biology but can 
also function as a barrier protective factor in the colon.[18,34] HIF1α protein is rapidly 
degraded unless it is stabilised by pro-inflammatory cytokines or hypoxic conditions. 
Therefore, we next investigated if HIF1α protein was expressed in the lesions apart from its 
transcriptional upregulation. There was an increase of nuclear HIF1α protein expression in 
the lesions compared with the surrounding mucosa and the distal colon (fig 5A). The pattern 
of HIF1α overexpression was confined to the surface epithelium of sulindac-induced lesions. 
However, this overexpression was not accompanied by upregulation of the Hif1α responsive 
genes CD73 and ITF, which are important mediators of epithelial barrier protection. For 
CD73, there was a gradient of increasing expression from proximal to the distal colon, where 
CD73 was expressed more than 100-fold higher than in the P1 region (fig 5B). ITF also 
showed higher expression in the distal colon compared to the proximal colon.  
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 Mucosal damage was profound in the lesions and resulted in crypt elongation and 
increased cell proliferation as assessed by immunohistochemistry for the proliferation marker 
Ki67 compared to normal mucosa (fig 5C,E). Ki67 positive cells were found at the 
epithelium surface in the lesions, while in normal conditions they were confined to the 
proliferative zone of the crypt base. Many of the cells that were positive for HIF1α also 
stained positive for Ki67 (fig 5D arrows). We conclude that HIF1α is upregulated by the 
sulindac diet in the P2 region and that the HIF1α protein is stabilised in epithelial cells that 
have proliferative potential. 
Next we investigated if HIF1α protein expression at the site of the lesions was 
associated with hypoxia, as it has been suggested that NSAID-induced tissue ulceration 
observed in some patients is caused by reduced blood supply to the site of damage.[35] We 
used pimonidazole, a previously validated hypoxia marker and detected positive staining in 
the region of the mucosal folds, but also in the rectum and intermittently in other regions 
(supplementary fig 3). Similar pattern of hypoxia staining was seen in both sulindac fed and 
control mice. Since any variation in tissue collection or fixation can affect the staining 
intensity between different mice, it cannot be determined if sulindac increased hypoxia. 
However, it can be concluded that the site of the lesions was prone to hypoxia, but this was 
not the only region affected.  
 
Hif1α  expression is pro-inflammatory in the proximal colon lesions. 
To determine whether HIF1α has a pro-inflammatory rather than protective function 
in the proximal colon, we analysed mice deficient for HIF1α in the intestinal epithelial cells 
(IEC), VILcrecre/+ HIF1α∆/F (HIF1α∆/∆IEC) and the control genotype VILcre+/+ HIF1α∆/F 
(HIF1α∆/F), which has retained HIF1α expression in the colon epithelium from the floxed 
allele. Recombination efficiency was high for both the proximal (97%) and the distal (95%) 
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colon epithelium and there was a 20-fold decrease in HIF1α mRNA expression in the 
mucosa of HIF1α∆/∆IEC mice. The two groups developed similar numbers of macroscopic 
lesions with the sulindac diet, but there was a small but non-significant decrease in the total 
surface area of the lesions in HIF1α∆/∆IEC mice. The frequency of adenocarcinoma was 15.4% 
in HIF1α∆/F and 5.3% in HIF1α∆/∆IEC mice. There was significantly less inflammation in the 
HIF1α∆/∆IEC group (fig 6, supplementary fig 4) than in the sibling controls HIF1α∆/F, 
indicating that lack of HIF1α expression in the colon alleviates the inflammatory response 
caused by sulindac. This was seen in both the non-involved tissue (p=0.0006) and in the 
lesions (p=0.0039). This indicates that HIF1α expressed by epithelial cells may play a role in 
modulating the inflammatory response in this mouse model.  
 
DISCUSSION 
This study was designed to determine if sulindac chemoprevention was affected by 
genetic defects that are important in colorectal cancer, such as p53 deficiency or the MMR 
defect. We have shown that sulindac was as effective in preventing AOM-induced distal 
colon tumours on the background of Msh2 or p53 deficiency as in the WT mice. However, 
the sulindac treatment also caused side effects in the proximal colon, which were more 
pronounced in mice with Msh2 or p53 deficiency. These results are in agreement with a 
recent report of intestinal and proximal colon carcinogenesis in response to sulindac, in mice 
heterozygous for a mutant Apc or the MMR gene Mlh1.[36]  
It was striking that the sulindac-induced lesions were confined to a specific region 
(P2) of the proximal colon. Small lesions with inflammatory cell infiltration became visible 
after just one week of sulindac diet. These early lesions showed surface crypt and epithelium 
damage suggesting initial mucosal irritation by sulindac. This region may be more 
susceptible to mechanical surface irritation because most water absorption from the bolus is 
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completed at the mucosal folds. Although the lesions progressed to neoplasia more frequently 
in mice with Msh2 or p53 deficiency, the macroscopic lesions developed to a similar extent 
in all mice, including the WT. Therefore, the initial insult to the mucosa was similar in all 
mice, suggesting that these early lesions were premalignant regardless of the genetic 
background. Our model does not single out a specific gene that is responsible for the early 
tissue inflammation in the P2 region, but has identified a combination of factors that 
characterised its unique response to the sulindac diet.  
A number of genes were differentially expressed between different parts of the colon 
or further regulated by the sulindac diet in the P2 region, including upregulation of HIF1α , 
PECAM and the NFκB target genes MIP-2, IL1β and COX-2. MIP-2 was strongly 
upregulated throughout the colon in sulindac-treated animals, but was most prominent in the 
lesions of the P2 region. MIP-2 is the mouse homolog of chemokine IL8, which is emerging 
as a pro-cancer master regulator of several important pathways.[32] Here we have shown for 
the first time that sulindac also upregulates IL8 in human colorectal cancer cells in vitro. IL8 
is overexpressed in many solid cancers, where it causes recruitment of infiltrating neutrophils 
to the tumour microenvironment, and promotes proliferation of human colon cancer cells in 
vitro.[32,37] MIP-2 also increases neutrophil and lymphocyte recruitment in the mouse 
intestine and increases inflammation in the DSS model of colitis.[38,39] The active role of 
epithelial cells as modulators of the inflammatory process is now well accepted. In addition, 
we observed upregulation of PECAM in the lesions. PECAM is a cell adhesion factor 
involved in leukocyte migration, and promotes migration of blood monocytes to tissue, 
particularly at sites of inflammation, where they maturate to tissue macrophages.[31,40] It is 
unclear if PECAM is a tumour promoter but it is expressed in colorectal cancer cells.[41] 
Thus upregulation of both MIP-2 and PECAM is associated with the presence of infiltrating 
inflammatory cells in the lesions of the P2 region.  
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Pro-inflammatory factors IL1β and COX-2 were also upregulated in the lesions. It is 
now well accepted that IL1β is a tumour promoter[42] and that COX-2, which is 
overexpressed in colorectal cancer, plays a key role in intestinal polyp formation.[43] It was 
unexpected that there was a slight increase of apoptosis in the lesions, as apoptosis is a 
chemopreventive mechanism linked to sulindac. Also, sulindac-induced tumorigenesis was 
previously shown to be associated with decreased apoptosis in ApcMin mice [13]. As we did 
not compare the effect of sulindac on apoptosis in all genetic backgrounds, the significance of 
this is unclear. However, these results are consistent with the findings in ulcerative colitis, as 
well as in DSS-induced colitis, where increased epithelial cell proliferation is associated with 
increased apoptosis.[26,27] We also observed slight downregulation of A20 in the lesions, 
which is consistent with its role as a major anti-apoptotic and anti-inflammatory protein in a 
mouse model of experimental colitis.[30] Interestingly, we did not observe a change in p21 
levels with sulindac in the proximal colon, whereas there was significant upregulation of p21 
in the distal colon. The chemopreventive effect of sulindac in APC1638+/- mice is abolished 
with targeted inactivation of p21.[28] Therefore, our results are consistent with the role of 
p21-mediated chemoprevention by sulindac in the distal colon.  
A striking aspect of the proximal lesions in our study was upregulation of HIF1α by 
the sulindac diet in the P2 region and protein overexpression of HIF1α in proliferating 
epithelial cells expressing Ki67. HIF1α is a transcription factor that activates many genes 
involved in cancer biology, including angiogenesis, cell proliferation/survival, glucose 
metabolism and invasion.[34] Increased HIF1α signalling in the intestinal epithelial cells 
leads to a hyperinflammatory reaction in the mouse colon and its overexpression is a feature 
of serrated colon adenocarcinomas in humans.[29,44] HIF1α is degraded in normoxic 
conditions unless stabilised by pro-inflammatory cytokines, such as IL1β through the NFkB 
pathway. The HIF1α pathway has been described as a link between inflammation and 
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cancer[45,46] but the HIF1α∆/∆IEC mice used here were not informative regarding the role of 
HIF1α in cancer. The reduction of colon inflammation in these mice suggests that HIF1α has 
a pro-inflammatory function in the sulindac model of proximal carcinogenesis. This was 
consistent with our observation that the HIF1α responsive genes ITF and CD73 that have 
been implicated in barrier protection,[47,48] were unaffected by the sulindac diet.  
NFκB activated genes, in particular IL6, are important in chronic colitis associated 
cancer.[9] Here we could not show strong upregulation of IL6, TNFα or ICAM by sulindac, 
but other NFκB targets MIP-2, IL1, and COX-2 were upregulated in the proximal lesions. 
Therefore, it appears that colon carcinogenesis in sulindac-induced lesions is associated with 
a different profile of NFκB target gene expression compared to the AOM/DSS model of 
colitis.[9] However, the role of NFκB activation in the colon carcinogenesis in this model can 
only be conclusively determined by using mice that have a specific deletion of IKKβ in the 
colon.  
This study has implications for proximal colon carcinogenesis in general. It is well 
known that there are significant differences in the molecular, pathological and clinical 
characteristics of tumours found in the proximal compared with the distal colon. For 
example, high microsatellite instability, gene promoter methylation and mucinous tumours 
are more common in the proximal colon and are associated with the serrated neoplasia 
pathway.[49,50] The tumours induced by sulindac share some features with proximal 
cancers, such as hyperplastic changes and a mucinous phenotype. Furthermore, serrated 
carcinomas have a different gene expression profile when compared with conventional 
carcinomas, including upregulation of HIF1α.[44] Although it is unknown whether there is a 
comparable region in the human colon which is susceptible to sulindac-induced tumours, the 
sulindac model of cancer may be suitable for the further study of early proximal 
carcinogenesis. 
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In conclusion, this is the first report of a simultaneous carcinogenic and 
chemopreventive effect of sulindac in the mouse colon. The localised effect of sulindac in the 
proximal colon is associated with the development of inflammatory lesions, which progress 
into malignancy more rapidly in the absence of Msh2 or p53. Furthermore, we provide 
evidence that dietary sulindac can modulate gene expression in the colon epithelium and thus 
may affect the epithelial-inflammatory cell crosstalk and regulation of the inflammatory 
process. Further investigation is necessary to determine if long-term use of sulindac has 
procarcinogenic effects in humans. 
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FIGURE LEGENDS  
Figure 1. Sulindac feed reduces the number and size of tumours in the distal colon but 
induces new lesions in the proximal colon. 
(A) Location of tumours in the distal colon induced by AOM. 
(B) Reduction in the total surface area of tumours in p53∆/∆, p53∆/+, Msh2∆/∆ and 
corresponding WT siblings with increasing sulindac concentration (*p≤ 0.05, compared to 
AOM-only treated mice).  
(C) Mean number of distal colon tumours per mouse showing a decrease in the number of 
AOM induced tumours with the sulindac treatment (*p≤ 0.05, compared to AOM-only 
treated mice). 
(D) Frequency of colon neoplasia in p53∆/∆, p53∆/+, Msh2∆/∆ and corresponding WT siblings. 
Sulindac diet decreased the frequency of distal colon neoplasia in AOM treated mice, while 
increasing the frequency of neoplasia in the proximal colon.  
(E) Location of sulindac-induced lesions in the mouse proximal colon. 
(F) Measurement of the total surface area of the proximal lesions induced by the sulindac diet 
in p53∆/∆, p53∆/+, Msh2∆/∆ and their WT siblings (*p≤ 0.05, compared to AOM-only treated 
mice). 
(G) Mean number of proximal lesions per mouse showing increase in the number of lesions 
with the sulindac treatment (*p≤ 0.05, compared to AOM-only treated mice). 
(H) Frequency of colon neoplasia in p53∆/∆, p53∆/+, Msh2∆/∆ and corresponding WT siblings, 
receiving the sulindac diet without the AOM treatment. Individual frequencies of neoplastic 






Figure 2. Proximal colon lesions induced by the sulindac diet progress from acute and 
chronic inflammation to adenocarcinoma. 
(A,B) H&E stained sections of macroscopically normal appearing proximal colon from 
sulindac-treated mice: low power photomicrographs showing mild hyperplasia of the 
epithelium and surface erosion (A&B, scale bars 100 µm); at higher power the area of 
erosion is characterised by a mixed inflammatory cell infiltrate and degenerative change of 
the surface epithelium without significant fibrosis (B insert, scale bar 20 µm). 
(C-E) H&E stained sections from ulcerated areas of the proximal colon from sulindac-treated 
mice: low power photomicrograph showing mucosal ulceration with early fibrosis (C, scale 
bar 200 µm; insert, scale bar 50 µm); well differentiated adenocarcinoma of the colon 
developing in an area of inflammation (D, scale bar 200 µm and insert, scale bar 50 µm); 
well differentiated mucinous adenocarcinoma of the colon developing in an area of 
inflammation (E, scale bar 200 µm and insert, scale bar 50 µm). 
(F) Quantification of sulindac and its sulfide and sulfone metabolites in the epithelium of the 
proximal and distal colon in seven sulindac fed mice (25 weeks). Error bars indicate SEM 
(*p≤ 0.05).  
(G) Schematic representation of the mouse colon. Most lesions are found in a well-defined 1 
cm section of the proximal colon, 2-3 cm from the caecum (P2). The sum of the lesion 
surface area per mouse is shown for the proximal and distal colon regions over 25 weeks of 





Figure 3.  Sulindac feed causes a slight increase of apoptosis in the mouse proximal 
colon. 
(A) Quantification of apoptosis (western blot analysis for cleaved caspase 3) in the two 
proximal colon regions (P1 and P2), middle (M) and distal (D) colon. Rate of apoptosis was 
higher in mice treated with sulindac compared to mice on control feed, particularly in the 
uninvolved region susceptible to sulindac induced lesions (P2; data for lesions not shown). 
WT mice received 320 ppm sulindac feed or control diet for 10 weeks. Relative activated 
caspase 3 expression in sulindac-treated animals is normalised to β-actin and is presented as a 
fold change to the corresponding colon region of control mice (3 mice per group). Error bars 
indicate SEM (*p≤ 0.05). 
(B) Western blot analysis for p21 expression in the colon mucosa of WT mice, treated with 
the control or 320 ppm sulindac diet for 10 weeks (7-8 per group). Relative p21 expression in 
sulindac-treated animals is normalised to β-actin and is presented as a fold change to the 
corresponding colon region of control mice. Error bars indicate SEM (*p≤ 0.05). 
 
Figure 4. Sulindac feed modulates the expression of pro-inflammatory genes in specific 
regions of the mouse colon. 
(A) qPCR analysis of Hif1α, MIP-2, IL1β, Cox-2, TNFα, IL6, ICAM1, iNOS, A20 and 
PECAM in the colon mucosa of control and sulindac treated WT mice (n=4). mRNA 
expression was normalised to the housekeeping gene rpl19. Graphs represent fold change 
except for IL6, where no expression was detected in the control mice. Error bars indicate 
SEM. Only statistically significant comparisons are shown (* p≤ 0.05).  
(B) qPCR analysis of  ICAM1, TNFα, IL6 and IL8 expression in HCT15 cells, unstimulated 
or stimulated with 50 µM sulindac sulfide or 20 ng/ml TNFα for 4 hours. Results are mean of 
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three independent experiments. mRNA expression was normalised to the housekeeping gene 
GAPDH. Error bars indicate SEM (* p≤ 0.05). 
  
Figure 5. Sulindac fed mice show stabilisation of HIF1α  protein in the inflammatory 
lesions (P2) developing in the mouse colon, where HIF1α  is expressed in Ki-67 positive 
epithelial cells.    
 (A) Immunohistochemistry analysis of Hif1α expression. Nuclear HIF-1α expression was 
increased in the surface epithelium of sulindac-induced lesions. Quantification of Hif1α IHC 
staining (H score) from sulindac treated WT mice. 
(B) qPCR analysis for ITF and CD73 mRNA expression normalised to Rpl 19 in the colon 
mucosa of control and sulindac treated WT mice. Error bars are SEM. Only statistically 
significant comparisons are shown (* p≤ 0.05). 
(C)  Immunohistochemistry analysis of the proliferation marker Ki67. Ki67 expression in 
normal colon (upper panel) is confined to the proliferative zone of the crypt base, but is found 
throughout sulindac-induced lesions (lower panel). Scale bars 50 µm. 
(D) Co-expression of Hif1α and Ki67 in serial sections of sulindac-induced lesions (red 
arrows). Scale bars 50 µm. 
(E) Quantification of the proliferative index, Ki67 in sulindac treated WT mice showing 
higher proliferation in lesions than the surrounding uninvolved mucosa. Bars represent mean 
percentage of crypt Ki67 positive cells. Error bars indicate SEM. 
 
Figure 6. Loss of Hif1α in the colon epithelium reduces sulindac-induced inflammation. 
(A) Total surface area of proximal lesions per mouse averaged per genotype in HIF1α∆/∆IEC 
and HIF1α∆/f mice receiving the sulindac diet. Error bars indicate SEM (p=NS).  
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(B) Histopathology assessment of inflammation in proximal lesions and uninvolved colon 
biopsies. Inflammation score is significantly reduced in HIF1α∆/∆IEC mice compared with 
HIF1α∆/f mice (p=0.0039, lesions; p=0.0006, uninvolved tissue). Bars indicate percentage of 
specimens in each inflammation category; 0= no inflammation, 1= mild, 2=moderate and 
3=severe inflammation. The inflammation scores for specific regions of the mouse colon are 
shown in supplementary figure 4.  
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